S&P 500   3,922.73 (-1.90%)
DOW   33,452.93 (-1.46%)
QQQ   281.13 (-2.26%)
AAPL   142.51 (-2.81%)
MSFT   244.40 (-2.32%)
META   114.41 (-6.55%)
GOOGL   96.80 (-2.69%)
AMZN   88.45 (-2.81%)
TSLA   179.23 (-1.76%)
NVDA   159.20 (-4.15%)
NIO   13.24 (+3.44%)
BABA   91.13 (+0.67%)
AMD   69.89 (-5.07%)
T   19.11 (+1.92%)
MU   53.47 (-1.05%)
CGC   3.65 (-15.51%)
F   13.19 (-1.42%)
GE   84.70 (+0.05%)
DIS   92.39 (-3.69%)
AMC   6.79 (-8.86%)
PYPL   72.02 (-2.17%)
PFE   49.60 (-2.23%)
NFLX   305.15 (-2.38%)
S&P 500   3,922.73 (-1.90%)
DOW   33,452.93 (-1.46%)
QQQ   281.13 (-2.26%)
AAPL   142.51 (-2.81%)
MSFT   244.40 (-2.32%)
META   114.41 (-6.55%)
GOOGL   96.80 (-2.69%)
AMZN   88.45 (-2.81%)
TSLA   179.23 (-1.76%)
NVDA   159.20 (-4.15%)
NIO   13.24 (+3.44%)
BABA   91.13 (+0.67%)
AMD   69.89 (-5.07%)
T   19.11 (+1.92%)
MU   53.47 (-1.05%)
CGC   3.65 (-15.51%)
F   13.19 (-1.42%)
GE   84.70 (+0.05%)
DIS   92.39 (-3.69%)
AMC   6.79 (-8.86%)
PYPL   72.02 (-2.17%)
PFE   49.60 (-2.23%)
NFLX   305.15 (-2.38%)
S&P 500   3,922.73 (-1.90%)
DOW   33,452.93 (-1.46%)
QQQ   281.13 (-2.26%)
AAPL   142.51 (-2.81%)
MSFT   244.40 (-2.32%)
META   114.41 (-6.55%)
GOOGL   96.80 (-2.69%)
AMZN   88.45 (-2.81%)
TSLA   179.23 (-1.76%)
NVDA   159.20 (-4.15%)
NIO   13.24 (+3.44%)
BABA   91.13 (+0.67%)
AMD   69.89 (-5.07%)
T   19.11 (+1.92%)
MU   53.47 (-1.05%)
CGC   3.65 (-15.51%)
F   13.19 (-1.42%)
GE   84.70 (+0.05%)
DIS   92.39 (-3.69%)
AMC   6.79 (-8.86%)
PYPL   72.02 (-2.17%)
PFE   49.60 (-2.23%)
NFLX   305.15 (-2.38%)
S&P 500   3,922.73 (-1.90%)
DOW   33,452.93 (-1.46%)
QQQ   281.13 (-2.26%)
AAPL   142.51 (-2.81%)
MSFT   244.40 (-2.32%)
META   114.41 (-6.55%)
GOOGL   96.80 (-2.69%)
AMZN   88.45 (-2.81%)
TSLA   179.23 (-1.76%)
NVDA   159.20 (-4.15%)
NIO   13.24 (+3.44%)
BABA   91.13 (+0.67%)
AMD   69.89 (-5.07%)
T   19.11 (+1.92%)
MU   53.47 (-1.05%)
CGC   3.65 (-15.51%)
F   13.19 (-1.42%)
GE   84.70 (+0.05%)
DIS   92.39 (-3.69%)
AMC   6.79 (-8.86%)
PYPL   72.02 (-2.17%)
PFE   49.60 (-2.23%)
NFLX   305.15 (-2.38%)
NASDAQ:GNPX

Genprex - GNPX Stock Forecast, Price & News

$1.23
-0.06 (-4.65%)
(As of 12/6/2022 03:03 PM ET)
Add
Compare
Today's Range
$1.23
$1.27
50-Day Range
$1.27
$1.47
52-Week Range
$1.17
$3.62
Volume
131 shs
Average Volume
74,625 shs
Market Capitalization
$59.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GNPX stock logo

About Genprex (NASDAQ:GNPX) Stock

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Receive GNPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter.

GNPX Stock News Headlines

See More Headlines
Receive GNPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter.

GNPX Company Calendar

Last Earnings
4/01/2019
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/29/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GNPX
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-19,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.86 per share

Miscellaneous

Free Float
42,939,000
Market Cap
$59.06 million
Optionable
Not Optionable
Beta
-0.33

Key Executives

  • Mr. John Rodney Varner (Age 65)
    Co-Founder, Chairman, Pres & CEO
    Comp: $747.18k
  • Mr. Ryan M. Confer M.S. (Age 40)
    Chief Financial Officer
    Comp: $522.67k
  • Ms. Catherine M. Vaczy Esq. (Age 61)
    Exec. VP, Gen. Counsel, Corp. Sec. & Chief Strategy Officer
    Comp: $597.58k
  • Dr. Hemant Kumar C.P.M. (Age 59)
    EMBA, Ph.D., Chief Manufacturing & Technology Officer
  • Ms. Kalyn Dabbs
    Sr. Mang. of Communications & Marketing
  • Mr. David M. Schloss
    Sr. VP of HR
  • Mr. Thomas C. Gallagher Esq.
    Sr. VP of Intellectual Property & Licensing
  • Dr. William E. Gannon Jr.
    Member of Clinical Advisory Board & VP of Regulatory Affairs
  • Dr. Mark S. Berger M.D. (Age 67)
    Chief Medical Officer
  • Mr. Greg Jancarik C.M.A.
    CPA, M.B.A., Corp. Controller













GNPX Stock - Frequently Asked Questions

How have GNPX shares performed in 2022?

Genprex's stock was trading at $1.31 on January 1st, 2022. Since then, GNPX stock has decreased by 1.5% and is now trading at $1.29.
View the best growth stocks for 2022 here
.

When is Genprex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our GNPX earnings forecast
.

How were Genprex's earnings last quarter?

Genprex, Inc. (NASDAQ:GNPX) posted its quarterly earnings results on Monday, April, 1st. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.10.

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), iBio (IBIO) and Advanced Micro Devices (AMD).

What is Genprex's stock symbol?

Genprex trades on the NASDAQ under the ticker symbol "GNPX."

Who are Genprex's major shareholders?

Genprex's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.17%), UBS Group AG (0.58%), Group One Trading L.P. (0.00%), Renaissance Technologies LLC (0.15%), Price T Rowe Associates Inc. MD (0.14%) and Tower Research Capital LLC TRC (0.04%).
View institutional ownership trends
.

How do I buy shares of Genprex?

Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genprex's stock price today?

One share of GNPX stock can currently be purchased for approximately $1.29.

How much money does Genprex make?

Genprex (NASDAQ:GNPX) has a market capitalization of $61.95 million. The company earns $-19,600,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How can I contact Genprex?

Genprex's mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The official website for the company is www.genprex.com. The company can be reached via phone at (877) 774-4679 or via email at investors@genprex.com.

This page (NASDAQ:GNPX) was last updated on 12/6/2022 by MarketBeat.com Staff